Establishing an Experienced Management Team
for Growth
MONTREAL, Feb. 18, 2020 /CNW Telbec/ - Mondias Natural
Products Inc. (TSXV: NHP) (the "Company" or
"Mondias") specializing in evidence-based natural products
for the healthcare and bio-agriculture markets today announces that
Mr. Mario Paradis CPA, CA, ICD.D has joined the Company as Chief
Financial Officer (CFO). Prior to joining Mondias, Mr. Paradis
has held CFO roles in consumer healthcare companies such as Atrium
Innovations, Acasti Pharma, and Neptune Wellness Solutions.
![Logo: Mondias Natural Products (CNW Group/Mondias Natural Products Inc.) Logo: Mondias Natural Products (CNW Group/Mondias Natural Products Inc.)](https://mma.prnewswire.com/media/1091634/Mondias_Natural_Products_Inc__Mondias_Announces_New_Chief_Financ.jpg)
Mondias CEO Dr. Patrick Frankham
stated that "Mario is a great addition to our growing organisation.
Mr. Paradis brings with him an extensive background in corporate
finance, mergers and acquisitions, treasury, financial planning and
analysis, tax, investor relations, strategic planning and risk
management with a deep appreciation for Mondias and its unique
position driving natural products for healthcare, agriculture, and
functional beverages markets. Dr. Frankham also added, "I wish
to thank Mr. Sabino Di Paola for
supporting Mondias through the initial offering stage and wish him
luck in his business pursuits."
Mr. Paradis was until November
2019, Vice President and Chief Financial Officer at Neptune
Wellness Solutions where he participated in the transition from
consumer healthcare products to cannabis. Prior to that, he
was Vice President and Chief Financial Officer at Atrium,
which was acquired in 2014 by corporations backed by Permira funds
in a transaction valued at over $1.1
billion. He was also at Aeterna Zentaris, most notably as
Vice President Finance and Administration & Corporate
Secretary. Mr. Paradis began his career at PricewaterhouseCoopers
(PwC), where he successfully held senior positions primarily in
audit and tax.
Mr. Paradis is a member of the Canadian Chartered Professional
Accountants (CPA). He holds a Bachelor degree in Business, with a
specialty in Accounting, from Université du Québec à
Trois-Rivières.
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the healthcare,
bio-agriculture and organic markets. The company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries and greenhouses, in collaboration with McGill's Faculty
of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than statements of historical fact, that address activities,
events or developments that the Company believes, expects or
anticipates will or may occur in the future (including, without
limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by the use of the words
"may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include the Company's inability to obtain sufficient financing to
execute its business plan; competition; regulation; anticipated and
unanticipated costs and delays; the success of the Company's
research and development strategies; the ability to obtain orphan
drug status; the applicability of the discoveries made; the
successful and timely completion and uncertainties related to the
regulatory approval process; the timing of clinical trials; the
timing and outcomes of regulatory or intellectual property
decisions; and other risks disclosed in the Company's public
disclosure record on file with the relevant securities regulatory
authorities. Although the Company has attempted to identify
important factors that could cause actual results or events to
differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements in this news release are made as of the
date of this news release, and the Company does not undertake any
obligation to publicly update them to reflect new information or
subsequent events or otherwise except as required by applicable
securities legislation.
SOURCE Mondias Natural Products Inc.